| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/26/2005 | CN1186097C Pharmaceutical compositions comprising an aldose reductase inhibitor and an ACE inhibitor |
| 01/26/2005 | CN1186063C Medicine for treating diabetes and its complication |
| 01/26/2005 | CN1186049C Odor-free garlic extract capsule and its preparing process |
| 01/26/2005 | CN1186036C Diabetes treating medicine and its preparation method |
| 01/26/2005 | CN1186033C Health-care tea with blood fat, blood pressure and blood sugar reducing function and processing method thereof |
| 01/26/2005 | CN1186030C Composition for losing weight of mammal, products comprising the same and its application |
| 01/26/2005 | CN1186018C Method for preparing nano linolenic acid emulsion |
| 01/26/2005 | CN1186017C Process for preparing medicine for preventing and curing diabetes, hyperlipemia and obesity |
| 01/26/2005 | CN1186016C Compound iron-copper intensified nutrient agent |
| 01/26/2005 | CN1186013C Peroral medicine deliver controlled system providing temporal and spatial control |
| 01/25/2005 | US6846834 Antiinflammation agents |
| 01/25/2005 | US6846832 Highly selective monoamine oxidase B inhibitors; treating Alzheimer's disease, Parkinson's disease, and senile dementia |
| 01/25/2005 | US6846831 Method of treating the syndrome of lipodystrophy |
| 01/25/2005 | US6846829 N-heterocyclic derivatives as NOS inhibitors |
| 01/25/2005 | US6846828 Aminopyrimidine and aminopyridine anti-inflammation agents |
| 01/25/2005 | US6846827 Antiinflammatory agents; antiallergens; antiarthritic agents |
| 01/25/2005 | US6846824 E.g., ethyl 3-(4-(2-(3-oxo-2H-1,4-benzoxazin-4-yl)ethoxy)-phenyl-2-ethoxypropenoate where 1,4-benzothiazine or quinoxaline can be substituted for the benzoxazine ring; anticholesterol, diabetic agents; obesity; hyperlimpidemia |
| 01/25/2005 | US6846811 For treating psoriasis, inflammation, leukemia, colon cancer, breast cancer or prostate cancer |
| 01/25/2005 | US6846676 In Vivo production and delivery of erythropoietin or insulinotropin for gene therapy |
| 01/25/2005 | CA2123224C Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of t-lymphocytes |
| 01/20/2005 | WO2005006807A1 Transmitter of wireless microphone, receiver for wireless microphone, mobile information communication apparatus, and communication system for wireless microphone |
| 01/20/2005 | WO2005006806A1 Wireless microphone communication system |
| 01/20/2005 | WO2005005665A1 Method of evaluating compound efficacious in treating obesity |
| 01/20/2005 | WO2005005471A2 Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 01/20/2005 | WO2005005433A1 Therapeutic agent for hyperpotassemia and bone disease |
| 01/20/2005 | WO2005005423A1 Indolyl derivatives substituted with a thiazole ring and their use as ppar modulators |
| 01/20/2005 | WO2005005421A1 Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds |
| 01/20/2005 | WO2005005417A1 Pyrrole-2, 5-dione derivatives as liver x receptor modulators |
| 01/20/2005 | WO2005005416A1 Pyrrole-2, 5-dithione derivatives as liver x receptor modulators |
| 01/20/2005 | WO2005004990A1 Use of whey permeate for the treatment of metabolic syndrome |
| 01/20/2005 | WO2005004923A1 Tablet and process for producing the same |
| 01/20/2005 | WO2005004904A1 Method for treating diseases associated with modifications of qualitative and/ quantitative composition of blood extracellular dna (variants) |
| 01/20/2005 | WO2005004888A1 Lipids from methanotrophic bacteria for cholesterol reduction |
| 01/20/2005 | WO2005004789A2 Method for treating diseases associated with changes of qualitative and/ quantitative composition of blood extracellular dna |
| 01/20/2005 | WO2005004639A1 Process for producing liquid formulation containing raw yeast and liquid formulation |
| 01/20/2005 | WO2004105780A3 Compositions comprising gastrin compounds and their use in diabetes |
| 01/20/2005 | WO2004098641A3 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| 01/20/2005 | WO2004096172A3 Vector for oral administration |
| 01/20/2005 | WO2004091486A3 Compounds for the treatment of metabolic disorders |
| 01/20/2005 | WO2004089992A8 Modified acacia and use thereof |
| 01/20/2005 | WO2004089386A8 Antiobestic agent using hen’s egg antibody against digestive enzymes |
| 01/20/2005 | WO2004086878A3 Improved dietary fiber containing materials comprising low molecular weight glucan |
| 01/20/2005 | WO2004085448A3 Unsaturated phosphinyl-phosphonate phosphate transport inhibitors |
| 01/20/2005 | WO2004083208A8 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| 01/20/2005 | WO2004064742A9 Methods and compositions for p2x receptor calcium entry channels and other calcium entry mechanisms |
| 01/20/2005 | WO2003076443A9 Spiro compounds with npy antagonistic activity |
| 01/20/2005 | WO2003066881A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 01/20/2005 | WO2002050289A8 Methods for the production of multimeric proteins, and related compositions |
| 01/20/2005 | US20050015820 Using transgenic mouse tissue as model for monitoring agents that affect appetite, energy expenditure and caloric and food intake; dietetics and weight gain |
| 01/20/2005 | US20050014941 Cyanoalkylamino derivatives as protease inhibitors |
| 01/20/2005 | US20050014938 Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase |
| 01/20/2005 | US20050014841 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases |
| 01/20/2005 | US20050014836 Crystalline form of nateglinide |
| 01/20/2005 | US20050014833 Cyclic compound and ppar agonist |
| 01/20/2005 | US20050014831 Cancer, hypertension, obesity; diseases mediated by alteration of membrane structure and regulation of G-proteins or receptors |
| 01/20/2005 | US20050014825 Preparation and use of solidified oils |
| 01/20/2005 | US20050014819 Prenylflavonoids, chalcone derivatives, flavonols and/or glycosides; plant extracts; foods, beverages; insulin resistance |
| 01/20/2005 | US20050014815 Substituted 2-pyrrolidine-2-yl-1H-indole compounds |
| 01/20/2005 | US20050014814 Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia |
| 01/20/2005 | US20050014807 Therapeutic compounds for treating dyslipidemic conditions |
| 01/20/2005 | US20050014805 Hypotensive agents; antidiabetic agents; cardiovascular disorders; anticholesterol agents; anticancer agents |
| 01/20/2005 | US20050014803 Enzyme inhibitors |
| 01/20/2005 | US20050014799 In mixture with enzyme inhibitors and other active materials |
| 01/20/2005 | US20050014793 Pyridinone derivatives for treatment of atherosclerosis |
| 01/20/2005 | US20050014781 Ring fused pyrazole derivatives as CRF antagonists |
| 01/20/2005 | US20050014768 Antiinflammatory agents; analgesics |
| 01/20/2005 | US20050014766 Use of n-(indolecarbonyl-)piperazine derivatives |
| 01/20/2005 | US20050014757 Serotonin receptor antagonist; psychological disorders; side effect reduction |
| 01/20/2005 | US20050014741 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| 01/20/2005 | US20050014731 Treatment of Th1 dominated immunological disease states with non-endogenous gestagen compounds |
| 01/20/2005 | US20050014705 E.g., dimethylcarbamic acid, 2-oxo-3-benzyl-4-methyl-2H-1-benzopyran; affects both the Tumor Necrosis Factor alpha level and transcription activity of NuclearFactor kappa Beta; antiimmunoinflammatory agents and autoimmune properties; antiarthritis agents; rheummatic diseases; osteoporosis; leukemia |
| 01/20/2005 | US20050014704 Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof |
| 01/20/2005 | US20050014703 Cell differentiation, regeneration of epithelium pancreas cells into insulin producing beta-cells; administrering a peptidyl- peptidase activator |
| 01/20/2005 | US20050014699 Combinations of enzyme inhibitor-containing preparations and the use thereof |
| 01/20/2005 | US20050014693 Transmission and, or amplification of signals; oral or enteric administering, dissolving, absorption of peptide yy; obesity therapy |
| 01/20/2005 | US20050014689 Remedies for life style-related diseases or cibophobia and method of screening the same |
| 01/20/2005 | US20050014683 Solvent extraction from plant |
| 01/20/2005 | US20050014679 Genetic engineered insulin; antidiabetic agents |
| 01/20/2005 | US20050014222 Phosphatases which activate map kinase pathways |
| 01/20/2005 | US20050014187 Novel polypeptide hormone phosphatonin |
| 01/20/2005 | US20050013887 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors |
| 01/20/2005 | US20050013874 Suspension or particle-solvent mixture system of zinc-containing calcium phosphate microparticles and therapeutic agent for treating zinc deficiency |
| 01/20/2005 | US20050013866 Particulate vectors for improving oral absorption of active principles |
| 01/20/2005 | US20050013864 In situ administering; mixture of bone morphogenic protein and ethylene oxide-propylene oxide copolymer |
| 01/20/2005 | US20050013858 Sustained release formulation; shorter treatment duration; higher tolerance; fungal infections |
| 01/20/2005 | US20050013849 Pet food composition for regulating body weight and preventing obesity and related disorders in pets |
| 01/20/2005 | US20050013848 Fat or oil composition |
| 01/20/2005 | DE202004017554U1 Antidiabetic dietetic nutritional supplement, effective against type-1 and type-2 diabetes, comprises processed material from Hibiscus plants, especially okra |
| 01/20/2005 | CA2532833A1 Use of whey permeate for the treatment of metabolic syndrome |
| 01/20/2005 | CA2532150A1 Method of evaluating compound efficacious in treating obesity |
| 01/20/2005 | CA2532068A1 Pyrrole-2, 5-dithione derivatives as liver x receptor modulators |
| 01/20/2005 | CA2532056A1 Pyrrole-2, 5-dione derivatives as liver x receptor modulators |
| 01/20/2005 | CA2531418A1 Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds |
| 01/19/2005 | EP1498478A1 Method of forming pancreatic beta cells from mesenchymal cells |
| 01/19/2005 | EP1498425A1 Use of glucagone-like-peptide 1 (GLP-1) derivatives for the preparation of pharmaceutical compositions |
| 01/19/2005 | EP1498150A1 Delivery of solid drug compositions |
| 01/19/2005 | EP1498125A1 Use of compounds having ccr antagonism |
| 01/19/2005 | EP1498124A2 The use of inhibitors of the renin-angiotensin system |
| 01/19/2005 | EP1497470A2 Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
| 01/19/2005 | EP1497436A1 Compositions for delivering enzymes involved in amino acid metabolism using recombinant adeno-associated virus virons (raav virons), and method and use for treating amino acid metabolic disorders using such raav virons |